Technical analysis of Dogwood Therapeutics, Inc. (DWTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia.
Price Performance
| 1 month | -20.56% |
| 3 months | +9.68% |
| Year-to-date | -59.13% |
| 1 year | -65.31% |
| 3 years | -93.33% |
| 5 years | -98.67% |
52-Week Range
| 52-week High | $9.50 |
| 52-week Low | $1.28 |
| Avg Volume (90d) | 76K |
Technical Indicators
| SMA 50 | $1.89 |
| SMA 200 | $2.56 |
| 30-day Volatility (annualised) | 91.3% |
| Price vs SMA 50 | -10.1% |
| Price vs SMA 200 | -33.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.21 | |
| 2025-11 | $6.52 | +5.0% |
| 2025-12 | $4.16 | -36.2% |
| 2026-01 | $2.79 | -32.9% |
| 2026-02 | $2.85 | +2.2% |
| 2026-03 | $2.11 | -26.0% |
| 2026-04 | $1.43 | -32.2% |
| 2026-05 | $1.69 | +18.2% |
| 2026-06 | $1.61 | -4.7% |
| 2026-07 | $1.64 | +1.9% |
| 2026-08 | $2.58 | +57.3% |
| 2026-09 | $1.70 | -34.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.70 |
| Market Cap | $57M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.76 |
| EV / EBITDA | -2.30 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.89 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -1.29 |